Given that combination therapies involving vascular-targeting drugs with chemotherapy or immunotherapy are common in CRC treatment, we employed a CT26 colon carcinoma subcutaneous tumor model to evaluate the effects of combining the autophagy inhibitor SBI-0206965 with low-dose chemotherapy (5-fluorouracil, 5-FU) or anti-PD-1 monoclonal antibodies. The gene discussed is PDCD1; the disease is colon carcinoma.